Pages that link to "Q28369030"
Jump to navigation
Jump to search
The following pages link to Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. (Q28369030):
Displaying 50 items.
- Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors (Q24554340) (← links)
- Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains (Q27640076) (← links)
- Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir (Q27650863) (← links)
- Molecular Characterization of Clinical Isolates of Human Immunodeficiency Virus Resistant to the Protease Inhibitor Darunavir (Q27656031) (← links)
- HIV-1 Protease-Substrate Coevolution in Nelfinavir Resistance (Q27683192) (← links)
- A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir (Q28344112) (← links)
- A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site (Q28344457) (← links)
- In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632 (Q28344594) (← links)
- ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia (Q28469175) (← links)
- Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1 (Q28469342) (← links)
- Model system for high-throughput screening of novel human immunodeficiency virus protease inhibitors in Escherichia coli (Q33204167) (← links)
- HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions (Q33262963) (← links)
- In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1 (Q33291158) (← links)
- An evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope. (Q33307183) (← links)
- Pairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease (Q33503921) (← links)
- Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors (Q33770040) (← links)
- Indinavir: a review of its use in the management of HIV infection (Q33826230) (← links)
- Machine learning on normalized protein sequences. (Q33858855) (← links)
- Nelfinavir: an update on its use in HIV infection (Q33897234) (← links)
- Genotypic testing for human immunodeficiency virus type 1 drug resistance (Q33906239) (← links)
- Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones (Q33935276) (← links)
- A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 (Q33979107) (← links)
- Efficient identification of human immunodeficiency virus type 1 mutants resistant to a protease inhibitor by using a random mutant library (Q34005107) (← links)
- HIV drug resistance and viral fitness. (Q34050677) (← links)
- A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes (Q34102058) (← links)
- Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. (Q34113737) (← links)
- Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir (Q34140913) (← links)
- Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precur (Q34344036) (← links)
- Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen (Q34680647) (← links)
- HIV-1 genotypic and phenotypic resistance (Q34876000) (← links)
- In Vivo Validation of a Bioinformatics Based Tool to Identify Reduced Replication Capacity in HIV-1 (Q34991044) (← links)
- Molecular Basis for Drug Resistance in HIV-1 Protease (Q35260370) (← links)
- Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity (Q35689381) (← links)
- A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies (Q35742512) (← links)
- Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial (Q35885190) (← links)
- Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes (Q35927934) (← links)
- Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. (Q36047851) (← links)
- Hepatotoxicity and nelfinavir: a meta-analysis (Q36119804) (← links)
- Nelfinavir: a review of its use in the management of HIV infection (Q36286228) (← links)
- Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir (Q36424925) (← links)
- Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference (Q36483991) (← links)
- Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems (Q36543455) (← links)
- R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen (Q36880577) (← links)
- Clinical significance of human immunodeficiency virus type 1 replication fitness (Q36969857) (← links)
- The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. (Q37018369) (← links)
- Novel Enzyme-Linked Minisequence Assay for Genotypic Analysis of Human Immunodeficiency Virus Type 1 Drug Resistance (Q37058422) (← links)
- GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro (Q37115695) (← links)
- Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance (Q37410823) (← links)
- Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases (Q37489580) (← links)
- Diversity of human immunodeficiency virus type 1 subtype A and CRF03_AB protease in Eastern Europe: selection of the V77I variant and its rapid spread in injecting drug user populations (Q37567877) (← links)